- Home
- PFN vs ADPT Comparison
PFN vs ADPT Comparison
Compare PFN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFN
- ADPT
- Stock Information
- Founded
- PFN 2004
- ADPT 2009
- Country
- PFN United States
- ADPT United States
- Employees
- PFN N/A
- ADPT N/A
- Industry
- PFN Finance/Investors Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFN Finance
- ADPT Health Care
- Exchange
- PFN Nasdaq
- ADPT Nasdaq
- Market Cap
- PFN 661.3M
- ADPT 749.7M
- IPO Year
- PFN N/A
- ADPT 2019
- Fundamental
- Price
- PFN $7.48
- ADPT $4.69
- Analyst Decision
- PFN
- ADPT Buy
- Analyst Count
- PFN 0
- ADPT 4
- Target Price
- PFN N/A
- ADPT $6.50
- AVG Volume (30 Days)
- PFN 331.7K
- ADPT 1.3M
- Earning Date
- PFN 01-01-0001
- ADPT 11-07-2024
- Dividend Yield
- PFN 11.66%
- ADPT N/A
- EPS Growth
- PFN N/A
- ADPT N/A
- EPS
- PFN N/A
- ADPT N/A
- Revenue
- PFN N/A
- ADPT $177,282,000.00
- Revenue This Year
- PFN N/A
- ADPT $3.82
- Revenue Next Year
- PFN N/A
- ADPT $20.38
- P/E Ratio
- PFN N/A
- ADPT N/A
- Revenue Growth
- PFN N/A
- ADPT N/A
- 52 Week Low
- PFN $5.94
- ADPT $2.28
- 52 Week High
- PFN $7.58
- ADPT $6.70
- Technical
- Relative Strength Index (RSI)
- PFN 46.04
- ADPT 44.21
- Support Level
- PFN $7.32
- ADPT $4.27
- Resistance Level
- PFN $7.49
- ADPT $6.70
- Average True Range (ATR)
- PFN 0.06
- ADPT 0.45
- MACD
- PFN -0.00
- ADPT -0.15
- Stochastic Oscillator
- PFN 55.36
- ADPT 17.28
About PFN PIMCO Income Strategy Fund II
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).